APP and Alzheimer disease: Among these proteins in amyloidome, SFRP1 (a regulator of WNT signaling) was reported to affect the formation of Aβ oligomers, as SFRP1 inhibition reduces plaque formation and partially rescues cognitive deficits in an AD mouse model (APP/PS1 mice), supporting its role in AD pathogenesis [169].